Activating mutations of FLT3 (FMS-Like Tyrosine kinase-3) are the most common molecular abnormality in acute myeloid leukemia (AML). Their presence is associated with a worse prognosis, and the recognition of this has led to the development of several new small molecule FLT3 tyrosine kinase inhibitors. In this review, we summarize these developments and compare and contrast these novel agents both with regards to the assays used to characterize them as well as to their clinical potential.
About this chapter
Cite this chapter as:Mark Levis, Donald Small ;
Small Molecule FLT3 Tyrosine Kinase Inhibitors, Frontiers in Medicinal Chemistry (2006) 3: 399. https://doi.org/10.2174/978160805206610603010399
Bentham Science Publisher